The IκB function of NF-κB2 p100 controls stimulated osteoclastogenesis

Journal of Experimental Medicine

Volumn 198, Issue 5, 2003, Pages 771-781

  Novack, Deborah Veis ^a   Yin, Li ^a   Hagen Stapleton, Amanda ^a   Schreiber, Robert D ^a   Goeddel, David V ^b   Ross, F Patrick ^a   Teitelbaum, Steven L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AMGEN INC   (United States)

Author keywords

Bone remodeling physiology; Cultured cells physiology; MAP kinase kinase kinases; Mice knockout; Murine RANKL

Indexed keywords

CYTOKINE RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN KAPPA CHAIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN P52; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR P100; UNCLASSIFIED DRUG; CARRIER PROTEIN; I KAPPA B; MEMBRANE PROTEIN; NF KAPPA B KINASE; NF-KAPPA B KINASE; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, MOUSE; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL FUNCTION; CELL STIMULATION; COMPLEX FORMATION; MONONUCLEAR CELL; MOUSE; MULTIGENE FAMILY; MULTINUCLEAR CELL; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PROCESSING; STEM CELL; TRANSACTIVATION; TRANSCRIPTION REGULATION; ANIMAL; BONE TUMOR; CYTOLOGY; GENETICS; METABOLISM; MOUSE MUTANT; MOUSE STRAIN; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BONE MARROW CELLS; BONE NEOPLASMS; CARRIER PROTEINS; I-KAPPA B PROTEINS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; NF-KAPPA B; NF-KAPPA B P52 SUBUNIT; OSTEOCLASTS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEM CELLS;

EID: 0042386014     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20030116     Document Type: Article

References (43)

1. Teitelbaum, S.L. 2000. Bone resorption by osteoclasts. Science. 289:1504-1508.
2. Ghosh, S., M.J. May, and E.B. Kopp. 1998. NF-κB and REL proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16:225-260.
3. Rothwarf, D.M., and M. Karin. 1999. The NF-κB activation pathway: a paradigm in information transfer from membrane to nucleus. Sci. STKE. 1999:RE1.
4. Palombella, V.J., O.J. Rando, A.L. Goldberg, and T. Maniatis. 1994. The ubiquitin-proteasome pathway is required for processing of the NF-κB1 precursor protein and the activation of NF-κB. Cell. 78:773-785.
5. Heusch, M., L. Lin, R., Geleziunas, and W.C. Greene. 1999. The generation of nfkb2 p52: mechanism and efficiency. Oncogene. 16:6201-6208.
6. Rice, N.R., M.L. MacKichan, and A. Israel. 1992. The precursor of NF-κ p50 has IκB-like functions. Cell. 71:243-253.
7. Scheinman, R.I., A.A. Beg, and J. Baldwin, A.S. 1993. NF-κB p100 (Lyt-10) is a component of H2TF1 and can function as an IκB-like molecule. Mol. Cell. Biol. 13:6089-6101.
8. Paxian, S., S. Liptay, A. Alder, H. Hameister, and R.M. Schmid. 1999. Genomic organization and chromosomal mapping of mouse nuclear factor kappa B2 (NFKB2). Immunogenetics. 49:743-750.
9. Xiao, G., E.W. Harhaj, and S.-C. Sun. 2001. NF-κB-inducing kinase regulates the processing of NF-κB2 p100. Mol. Cell. 7:401-409.
10. Senftleben, U., Y. Cao, G. Xiao, F.R. Greten, G. Krahn, G. Bonizzi, Y. Chen, Y. Hu, A. Fong, S.-C. Sun, et al. 2001. Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway. Science. 293:1495-1499.
11. Caamano, J.H., C. Rizzo, S.K. Durham, D.S. Barton, C. Kaventos-Suarez, C.M. Snapper, and R. Bravo. 1998. Nuclear factor (NF)-κB (p100/p52) is required for nomial splenic microarchitecture and B cell-mediated immune responses. J. Exp. Med. 187:185-196.
12. Franzoso, G., L. Carlson, L. Poljak, E.W. Shores, S. Epstein, A. Leonardi, A. Grinberg, T. Tran, T. Scharton-Kersten, M. Anver, et al. 1998. Mice deficient in nuclear factor (NF)-κB/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J. Exp. Med. 187:147-159.
13. Miyawaki, S., Y. Nakamura, H. Suzuka, M. Koba, R. Yasumizu, S. Ikehara, and Y. Shibata. 1994. A new mutation, aly, that induces a generalized lack of lymph nodes accompanied by immunodeficiency in mice. Eur. J. Immunol. 24:429-434.
14. Matsushima, A., T. Kaisho, P.D. Rennert, H. Nakano, K. Kurosawa, D. Uchida, K. Takeda, S. Akira, and M. Matsumoto. 2001. Essential role of nuclear factor (NF)-κB-inducing kinase and inhibitor of κB (IκB) kinase α in NF-κB activation through lymphotoxin β receptor, but not through tumor necrosis factor receptor I. J. Exp. Med. 193:631-636.
15. Shinkura, R., K. Kitada, F. Matsuda, K. Tashiro, K. Ikuta, M. Suzuki, K. Kogishi, T. Serikawa, and T. Honjo. 1999. Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-kappa b-inducing kinase. Nat. Genet. 22:74-77.
16. Yamada, T., T. Mitani, K. Yorita, D. Uchida, A. Matsushima, K. Iwamasa, S. Fujita, and M. Matsumoto. 2000. Abnormal immune function of hemopoietic cells from alymphoplasia (aly) mice, a natural strain with mutant NF-kappa B-inducing kinase. J. Immunol. 165:804-812.
17. Ishikawa, H., D. Carrasco, E. Claudio, R.-P. Ryseck, and R. Bravo. 1997. Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-κB2. J. Exp. Med. 186:999-1014.
18. Yin, L., L. Wu, H. Wesche, C.D. Arthur, J.M. White, D.V. Goeddel, and R.D. Schreiber. 2001. Defective lymphotoxin-β receptor-induced NF-κB transcriptional activity in NIK-deficient mice. Science. 291:2162-2165.
19. Iotsova, V., J. Caamano, J. Loy, Y. Yang, A. Lewin, and R. Bravo. 1997. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat. Med. 3:1285-1289.
20. Kitazawa, R., R.B. Kimble, J.L. Vannice, V.T. Kung, and R. Pacifici. 1994. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J. Clin. Invest. 94:2397-2406.
21. Takeshita, S., K. Kaji, and A. Kudo. 2000. Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J. Bone Miner. Res. 15:1477-1488.
22. McHugh, K.P., K. Hodivala-Dilke, M.H. Zheng, N. Namba, J. Lam, D. Novack, X. Peng, F.P. Ross, R.O. Hynes, and S.L. Teitelbaum. 2000. Mice lacking β3 integrins are osteosclerotic because of dysfunctional osteoclasts. J. Clin. Invest. 105:433-440.
23. Onishi, M., T. Nosaka, K. Misawa, A.L.-F. Mui, D. Gorman, M. McMahon, A. Miyajima, and T. Kitamura. 1998. Identification and characterization of a constitutive active STAT5 mutant that promotes cell proliferation. Mol. Cell. Biol. 18:3871-3879.
24. Liptay, S., R.M. Schmid, E.G. Nabel, and G.J. Nabel. 1994. Transcriptional regulation of NF-κB2: evidence for κB-mediated positive and negative autoregulation. Mol. Cell. Biol. 14:7695-7703.
25. Parfitt, A.M., G.R. Mundy, G.D. Roodman, D.E. Hughes, and B. Boyce. 1996. A new model for the regulation of bone resorption, with particular reference to the effects of bisphonates. J. Bone Miner. Res. 11:150-159.
26. Jimi, E., S. Akiyama, T. Tsurukai, N. Okahashi, K. Kobayashi, N. Udagawa, T. Nishihara, N. Takahashi, and T. Suda. 1999. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J. Immunol. 163:434-442.
27. Franzoso, G., L. Carlson, L. Xing, L. Poljak, E.W. Shores, K.D. Brown, A. Leonardi, T. Tran, B.F. Boyce, and U. Siebenlist. 1997. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev. 11:3482-3496.
28. Song, H.Y., C.H. Regnier, C.J. Kirschning, D.V. Goeddel, and M. Rothe. 1997. Tumor necrosis factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-kappaB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2. Proc. Natl. Acad. Sci. USA. 94:9792-9796.
29. Malinin, N.L., M.P. Boldin, A.V. Kovalenko, and D. Wallach. 1997. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature. 385:540-544.
30. Garceau, N., Y. Kosaka, S. Masters, J. Hambor, R. Shinkura, T. Honjo, and R.J. Noelle. 2000. Lineage-restricted function of nuclear factor kappaB-inducing kinase (NIK) in transducing signals via CD40. J. Exp. Med. 191:381-386.
31. Claudio, E., K. Brown, S. Park, H. Wang, and U. Siebenlist. 2002. BAFF-induced NEMO-independent processing of NF-KB2 in maturing B cells. Nat. Immunol. 3:958-965.
32. Wei, S., M.W. Wang, S.L. Teitelbaum, and F.P. Ross. 2001. Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-κB and MAP kinase signaling. J. Biol. Chem. 21:6622-6630.
33. Coope, H.J., P.G.P. Atkinson, B. Huhse, M. Belich, J. Janzen, M.J. Holman, G.G.B. Klaus, L.H. Johnston, and S.C. Ley. 2002. CD40 regulates the processing of NF-κB2 p100 to p52. EMBO J. 21:5375-5385.
34. Mordmuller, B., D. Krappmann, M. Esen, E. Wegener, and C. Scheidereit. 2003. Lymphotoxin and lipopolysaccharide induce NF-κB-p52 generation by a co-translational mechanism. EMBO Rep. 4:82-87.
35. Lam, J., S. Takeshita, B.J.E., O. Kanagawa, F.P. Ross, and S.L. Teitelbaum. 2000. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106:1481-1488.
36. Duckett, C.S., N.D. Perkins, T.F. Kowalik, R.M. Schmid, E.S. Huang, A.S. Baldwin, Jr., and G.J. Nabel. 1993. Dimerization of NF-KB2 with RelA(p65) regulates DNA binding, transcriptional activation, and inhibition by an I kappaBalpha (MAD3). Mol. Cell. Biol. 13:1315-1322.
37. Dobrzanski, P., R.P. Ryseck, and R. Bravo. 1993. Both Nand C-terminal domains of RelB are required for full transactivation: role of the N-terminal leucine zipper-like motif. Mol. Cell. Biol. 13:1572-1582.
38. Cenci, S., M.N. Weitzmann, C. Roggia, N. Namba, D. Novack, and R. Pacifici. 2000. Estrogen deficiency induces bone loss by enhancing T cell production of TNFα. J. Clin. Invest. 106:1229-1237.
39. Keffer, J., L. Probert, H. Cazlaris, S. Georgopoulos, E. Kaslaris, D. Kioussis, and G. Kollias. 1991. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10:4025-4031.
40. Birkedal-Hansen, H. 1993. Role of cytokines and inflammatory mediators in tissue destruction. J. Periodontal Res. 28:500-510.
41. Abu-Amer, Y., F.P. Ross, J. Edwards, and S.L. Teitelbaum. 1997. Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its p55 receptor. J. Clin. Invest. 100:1557-1565.
42. Fuller, K., J.M. Lean, K.E. Bayley, M.R. Wani, and T.J. Chambers. 2000. A role for TGFβ1 in osteoclast differentiation and survival. J. Cell Sci. 113:2445-2453.
43. Kaneda, T., T. Nojima, M. Nakagawa, A. Ogasawara, H. Kaneko, T. Sato, H. Mano, M. Kumegawa, and Y. Hakeda. 2000. Endogenous production of TGF-β is essential for osteoclastogenesis induced by a combination of receptor activator of NF-κB ligand and macrophage-colony-stimulating factor. J. Immunol. 165:4254-4263.